TRI-SPRINTEC: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Barr	TRI-SPRINTEC	ethinyl estradiol; norgestimate	TABLET;ORAL-28	075808	ANDA	Teva Pharmaceuticals USA, Inc.	0555-9018-58	6 POUCH in 1 CARTON (0555-9018-58) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK	2003-12-29
Barr	TRI-SPRINTEC	ethinyl estradiol; norgestimate	TABLET;ORAL-28	075808	ANDA	Proficient Rx LP	63187-458-28	6 POUCH in 1 CARTON (63187-458-28) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK	2003-12-29
Barr	TRI-SPRINTEC	ethinyl estradiol; norgestimate	TABLET;ORAL-28	075808	ANDA	Preferred Pharmaceuticals Inc.	68788-6325-2	1 BLISTER PACK in 1 POUCH (68788-6325-2) / 1 KIT in 1 BLISTER PACK	2016-10-18
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 2, 2025

Introduction

Tri-Sprintec is a widely prescribed oral contraceptive pill combining ethinyl estradiol, ethinyl estradiol, and norgestimate, marketed primarily for birth control. As a combination hormonal contraceptive, Tri-Sprintec's active ingredients are produced by multiple pharmaceutical manufacturers, emphasizing the importance of understanding its supply chain for stakeholders. This article provides a comprehensive overview of suppliers involved in the production and distribution of Tri-Sprintec, highlighting key manufacturers, sourcing strategies, and market dynamics critical for industry professionals and healthcare providers.

Manufacturers and Original Suppliers

AbbVie Inc.

Tri-Sprintec is marketed by AbbVie Inc., a global biopharmaceutical company headquartered in Illinois, United States. AbbVie originally developed and commercialized the formulation, leveraging its extensive manufacturing infrastructure. As an innovator, AbbVie maintains primary responsibility for the formulation, marketing, and distribution logistics for Tri-Sprintec within authorized regions.

Active Pharmaceutical Ingredient (API) Suppliers

The core ingredients—ethinyl estradiol and norgestimate—are synthesized by multiple API manufacturers worldwide. These APIs are crucial to ensuring drug quality, potency, and compliance with regulatory standards.

Ethinyl Estradiol Suppliers:
Several companies supply high-quality ethinyl estradiol, including Lonza, APIS GmbH, and Hubei Ziting Pharmaceutical Co., Ltd. These firms operate under strict Good Manufacturing Practices (GMP) compliant facilities and are certified for international markets such as the United States (FDA), Europe (EMA), and Japan (PMDA).
Norgestimate Suppliers:
Norgestimate is a semi-synthetic steroid, with suppliers including Fapon Biotech, LGM Pharma, and Fresenius Kabi. These suppliers provide APIs conforming to pharmacopoeial standards, with some API batches reprocessed or recrystallized to meet specific pharmaceutical requirements.

Contract Manufacturers and Supply Chain Dynamics

Contract Manufacturing Organizations (CMOs)

Due to the complex nature of hormone synthesis and tablet formulation, AbbVie relies heavily on CMOs for manufacturing, coating, and packaging. Key CMOs include:

Hetero Labs Ltd.: An Indian pharmaceutical giant with extensive experience in steroid synthesis and formulation, supplying both APIs and finished dosage forms to global firms.
Samsung Biologics: While primarily focused on biologics, Samsung’s specialized facilities have expanded into oral solid dosage form manufacturing, offering flexible production for companies like AbbVie.
Catalent Inc.: A leading CMO providing formulation, fill-finish, and packaging services, ensuring high standards of quality and scalability.

Supply Chain Challenges and Mitigation

The supply chain for Tri-Sprintec faces challenges such as geopolitical risks, regulatory hurdles, and raw material shortages, especially for hormone APIs. To mitigate disruptions:

Diversification of Suppliers: AbbVie and partners source APIs from multiple regions, including Asia, Europe, and North America.
Strategic Stockpiling: Maintaining buffer stocks at manufacturing facilities mitigates supply gaps.
Regulatory Compliance: Suppliers adhere to cGMP standards, with periodic audits to ensure ongoing compliance.

Market and Regional Suppliers

Tri-Sprintec's distribution varies across regions, with regional suppliers often fulfilling local demands:

United States: Predominantly supplied directly by AbbVie’s manufacturing units and authorized contract manufacturers.
Europe: Sourced through regional distributors who liaise with European approved manufacturing facilities.
Asia: Manufacturing is often outsourced to local CMOs, with import regulations managed carefully to meet international quality standards.

Regulatory Influences on Supplier Selection

Regulatory bodies impose stringent requirements on pharmaceutical suppliers, emphasizing API purity, manufacturing practices, and documentation. AbbVie and its suppliers ensure compliance with:

U.S. Food and Drug Administration (FDA): Inspects and certifies API plants and manufacturing facilities.
European Medicines Agency (EMA): Ensures adherence to EU Good Manufacturing Practices.
Japanese Pharmaceuticals and Medical Devices Agency (PMDA): Regulates API imports complying with local standards.

These regulatory frameworks influence supplier choices, favoring established, internationally certified suppliers and CMOs to minimize approval risks.

Future Outlook and Supplier Trends

The global demand for contraceptive medications like Tri-Sprintec continues to grow, driven by expanding healthcare access and strategic family planning initiatives. Suppliers anticipate:

Increased API Production Capacity: New facilities in emerging markets, such as Southeast Asia, are scaling up API manufacturing.
Bioequivalence and Generic Development: Market entry of generics influences supplier dynamics, with some companies investing in innovative API synthesis methods.
Supply Chain Digitalization: Enhanced transparency and traceability through blockchain and digital platforms, improving supplier verification and compliance.

Key Considerations for Industry Stakeholders

Quality Assurance: Ensuring APIs and finished products meet pharmacopoeial standards remains paramount.
Supplier Diversification: Reducing dependence on single-source suppliers minimizes risks.
Regulatory Timelines: Staying compliant with evolving international standards drives supplier selection and quality control processes.
Cost Management: Balancing quality with cost efficiency influences sourcing strategies, especially amidst fluctuating raw material prices.

Key Takeaways

Multiple API Suppliers: The production of Tri-Sprintec's active ingredients involves numerous reputable suppliers across different regions, primarily in India, China, and Europe, ensuring supply security.
Contract Manufacturing: AbbVie relies on CMOs with extensive steroid synthesis expertise, with Indian and Asian manufacturers playing critical roles.
Regulatory Compliance: Suppliers must adhere to strict international standards, influencing supplier selection and quality assurance processes.
Supply Chain Risks: Geopolitical shifts, raw materials shortages, and regulatory changes require dynamic sourcing strategies.
Market Expansion: Growing global demand for contraceptives propels investments in API capacity and supply chain resilience.

FAQs

1. Who are the primary suppliers of the active ingredients in Tri-Sprintec?
Major suppliers include Lonza (ethinyl estradiol), APIS GmbH, and Hubei Ziting Pharmaceutical (ethinyl estradiol), along with Fapon Biotech, LGM Pharma, and Fresenius Kabi (norgestimate). These companies operate under cGMP standards to meet international regulatory requirements.

2. Does AbbVie manufacture all components of Tri-Sprintec in-house?
No. AbbVie primarily manages formulation, marketing, and distribution, relying on third-party API manufacturers and contract manufacturing organizations (CMOs) for raw ingredients and final dosage form production.

3. How does regulatory compliance influence supplier selection for Tri-Sprintec?
Suppliers must meet rigorous standards set by agencies such as the FDA, EMA, and PMDA. Certifications, audit reports, and compliance with pharmacopoeial standards are critical criteria in supplier selection to ensure product safety and efficacy.

4. Are there regional differences in the supply chain for Tri-Sprintec?
Yes. The supply chain varies across regions, with API suppliers and manufacturers in India, China, and Europe supplying different markets, often tailored to regional regulatory landscapes and manufacturing capabilities.

5. What future trends may impact the supply of Tri-Sprintec?
Anticipated trends include increased API manufacturing capacity in emerging markets, growth of generic contraceptives, advancements in digital supply chain management, and heightened regulatory requirements, all influencing supplier strategies.

Sources

[1] Abbott Laboratories and AbbVie Annual Reports.
[2] U.S. Food and Drug Administration (FDA) regulatory guidelines.
[3] European Medicines Agency (EMA) certifications and standards.
[4] Industry analyses of API manufacturing in India and China.
[5] Market research reports on contraceptive pharmaceuticals.

Suppliers and packagers for TRI-SPRINTEC

TRI-SPRINTEC

Suppliers for the Pharmaceutical Drug: Tri-Sprintec